In November, the 6th China International Import Expo (CIIE) was convened in Shanghai, under the auspices of the Ministry of Commerce of the People’s Republic of China and the Shanghai Municipal People’s Government. This event saw the participation of 3,400 companies from 154 countries and regions worldwide. CIIE, distinguished as the world’s premier national-level exhibition centred on the theme of imports, stands as a pivotal showcase supporting global trade liberalization, economic globalization, and China’s commitment to international openness.
Against this backdrop of international collaboration and abundant opportunities, JMM International Pty Ltd (JMM International Health) of Australia and Sinopharm Health Industry Co., Ltd. (Sinopharm Health), a member of the China National Pharmaceutical Group, entered into a significant cooperation agreement. This milestone was marked in the presence of senior leaders from officials from the Australian Trade and Investment Commission. Acting as the exclusive agent for JMM’s KAYAJ brand in the Chinese market over the next decade, Sinopharm Health is poised to introduce pharmaceutical-grade nutritional and health products from Australia to discerning Chinese consumers. Concurrently, JMM will collaborate with Sinopharm Health as an exhibitor during this year’s CIIE, where KAYAJ’s flagship products will make their debut before the Chinese audience.
Sinopharm Health operates in five major domains: nutrition and health care, health food and beverages, beauty and personal care, animal and plant health, and drugs and devices. Serving as the exclusive agent for over 200 renowned health brands in Europe and the United States, Sinopharm Health boasts a portfolio of more than 2,000 SKUs. In collaboration with China International Medical and Health Co., Ltd., its international operations encompass duty-free, medical care, and health care, aspiring to emerge as a modern life and health flagship enterprise integrating science, trade, and industry in alignment with the Healthy China strategy. Sinopharm Health life and health industry, forges strong alliances to introduce leading overseas health products, thereby delivering high-quality health products and services, including nutrition and health care, to the wider Chinese population.
JMM, an Australian enterprise dedicated to the research and promotion of pre-health concepts, features proprietary health products. JMM’s comprehenseive activities engages itself with ideas surrounding big health, health care talent training, and health care structure standard design. JMM is responsible for the development of KAYAJ health products, the TGA approval process, and production processing, complemented by independent health training services. Boasting a senior management team with over 30 years of extensive experience in the health sector, the company specializes in TGA-certified health food with natural and healthy ingredients. Supplied with an advanced research and development team, JMM is well-positioned to swiftly address emerging market needs.
This collaborative effort aims to enhance individual health awareness through knowledge-sharing with consumers, guided use of health care products under professional supervision, and addressing service and professionalism gaps in the health care products market. This partnership represents not only an amalgamation of values and principles but also a synergistic collaboration leveraging mutual strengths and shared resources on both domestic and international fronts.
Anticipating the introduction of KAYAJ’s new health concept to countless households in China, this collaboration signifies a promising step towards advancing health and well-being on a global scale.
